{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:37:35Z","timestamp":1758638255630},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,6,11]],"date-time":"2010-06-11T00:00:00Z","timestamp":1276214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s00347-010-2210-z","type":"journal-article","created":{"date-parts":[[2010,6,9]],"date-time":"2010-06-09T11:04:02Z","timestamp":1276081442000},"page":"124-131","source":"Crossref","is-referenced-by-count":8,"title":["Anti-VEGF-Therapie der exsudativen AMD"],"prefix":"10.1007","volume":"108","author":[{"given":"B.","family":"Heimes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lommatzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Zeimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gutfleisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Spital","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Pauleikhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,11]]},"reference":[{"key":"2210_CR1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.exer.2007.08.010","volume":"85","author":"Ablonczy","year":"2007","unstructured":"Ablonczy Z, Crosson CE (2007) VEGF modulation of retinal pigment epithelium resistance. Exp Eye Res 85:762\u2013771","journal-title":"Exp Eye Res"},{"key":"2210_CR2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ophtha.2006.10.045","volume":"114","author":"Boyer","year":"2007","unstructured":"Boyer DS, Antoszyk AN, Awh CC et al (2007) Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114:246\u2013252","journal-title":"Ophthalmology"},{"key":"2210_CR3","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444","journal-title":"N Engl J Med"},{"key":"2210_CR4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116:57\u201365","journal-title":"Ophthalmology"},{"key":"2210_CR5","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/archopht.125.11.1460","volume":"125","author":"Chang","year":"2007","unstructured":"Chang TS, Bressler NM, Fine JT et al (2007) Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 125:1460\u20131469","journal-title":"Arch Ophthalmol"},{"key":"2210_CR6","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/archopht.123.11.1507","volume":"123","author":"Dandekar","year":"2005","unstructured":"Dandekar SS, Jenkins SA, Peto T et al (2005) Autofluorescence imaging of choroidal neovascularization due to age-related macular degeneration. Arch Ophthalmol 123:1507\u20131513","journal-title":"Arch Ophthalmol"},{"key":"2210_CR7","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","volume":"143","author":"Fung","year":"2007","unstructured":"Fung AE, Lalwani GA, Rosenfeld PJ et al (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566\u2013583","journal-title":"Am J Ophthalmol"},{"key":"2210_CR8","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00417-008-0854-z","volume":"246","author":"Heimes","year":"2008","unstructured":"Heimes B, Lommatzsch A, Zeimer M et al (2008) Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD. Graefes Arch Clin Exp Ophthalmol 246:1229\u20131234","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2210_CR9","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.ophtha.2007.04.030","volume":"114","author":"Kaiser","year":"2007","unstructured":"Kaiser PK, Blodi BA, Shapiro H et al (2007) Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114:1868\u20131875","journal-title":"Ophthalmology"},{"key":"2210_CR10","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajo.2007.08.012","volume":"144","author":"Kaiser","year":"2007","unstructured":"Kaiser PK, Brown DM, Zhang K et al (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144:850\u2013857","journal-title":"Am J Ophthalmol"},{"key":"2210_CR11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/bjo.2006.095109","volume":"91","author":"McBain","year":"2006","unstructured":"McBain VA, Townend J, Lois N (2006) Fundus autofluorescence in exudative age-related macular degeneration. Br J Ophthalmol 91(4):491\u2013496","journal-title":"Br J Ophthalmol"},{"key":"2210_CR12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","volume":"145","author":"Regillo","year":"2008","unstructured":"Regillo CD, Brown DM, Abraham P et al (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:239\u2013248","journal-title":"Am J Ophthalmol"},{"key":"2210_CR13","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"2210_CR14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ophtha.2007.04.023","volume":"115","author":"Vaclavik","year":"2008","unstructured":"Vaclavik V, Vujosevic S, Dandekar SS et al (2008) Autofluorescence imaging in age-related macular degeneration complicated by choroidal neovascularization: a prospective study. Ophthalmology 115:342\u2013346","journal-title":"Ophthalmology"},{"key":"2210_CR15","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00417-007-0574-9","volume":"245","author":"Vujosevic","year":"2007","unstructured":"Vujosevic S, Vaclavik V, Bird AC et al (2007) Combined grading for choroidal neovascularisation: colour, fluorescein angiography and autofluorescence images. Graefes Arch Clin Exp Ophthalmol 245:1453\u20131460","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-010-2210-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-010-2210-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-010-2210-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T13:51:01Z","timestamp":1559051461000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-010-2210-z"}},"subtitle":["Prognostische Faktoren f\u00fcr den Therapieerfolg"],"short-title":[],"issued":{"date-parts":[[2010,6,11]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["2210"],"URL":"https:\/\/doi.org\/10.1007\/s00347-010-2210-z","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,11]]}}}